We are interested in defining better therapeutic approaches to the treatment of lung cancer patients. We explore the immune microenvironment of lung cancers, have identified potential mechanisms restricting immunologic response and potential targets for intervention. We have used CRISPR screening to find potential selective vulnerabilities that can be exploited therapeutically. We have generated and maintain a large library of well annotated patient-derived xenograft models to serve as a platform for discovery research. We use single cell technologies to understand tumor heterogeneity and plasticity, as potential contributors to both drug resistance and tumor metastasis. While we study many types of lung cancer, we have a particular interest in small cell lung cancer.
- Lineage plasticity and histologic transformation.
- SMARCA4 loss in lung adenocarcinoma.
- Selective dependencies and subtype-specific vulnerabilities in small cell lung cancer.
- Multiple approaches to DLL3 targeting.
- Regulation of small cell lung cancer metastasis.
- Epigenetic targeting and immune activation in lung cancer.
- Combinatorial therapeutics for lung cancer.
- Preclinical human tumor modeling in vivo.
Dr. Charles M. Rudin, completed his MD/PhD training in the MSTP Program of the Pritzker School of Medicine at the University of Chicago, with thesis work under the mentorship of molecular immunologist Ursula Storb. He stayed at Chicago for residency, fellowship, post-doctoral training in the cancer biology laboratory of Craig Thompson, and his first faculty job. Dr. Rudin moved to Johns Hopkins University as the founding co-Director of the Upper Aerodigestive Cancer Program, and served as Associate Cancer Center Director for Clinical Research. He joined Memorial Sloan Kettering as Chief of Thoracic Oncology in 2013.
- NCI Outstanding Investigator Award
- IASLC Lifetime Achievement Award
- NCI Directors Service Award
- PI of the NCI Small Cell Lung Cancer Research Consortium